New Zealand markets closed

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
283.63-3.89 (-1.35%)
At close: 04:00PM EST
283.50 -0.13 (-0.05%)
After hours: 07:10PM EST
Full screen
Trade prices are not sourced from all markets
Previous close287.52
Open288.57
Bid283.01 x 900
Ask287.00 x 2200
Day's range282.52 - 291.01
52-week range187.16 - 311.88
Volume789,153
Avg. volume1,204,891
Market cap40.843B
Beta (5Y monthly)0.21
PE ratio (TTM)14.46
EPS (TTM)19.62
Earnings date15 Feb 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est322.26
  • Motley Fool

    Why the FDA's Rejection of Eli Lilly's Alzheimer's Drug Is Actually Great News for the Stock

    When the Food and Drug Administration (FDA) rejects a key drug from a healthcare company, it can send the stock spiraling into a sell-off. In order for the FDA to be confident in a drug's effectiveness, it needs to have a large enough sample size to evaluate it. Unfortunately, in Eli Lilly's case, it simply didn't have enough data points for the agency to make a positive conclusion about the treatment and grant it accelerated approval.

  • Zacks

    Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know

    Biogen Inc. (BIIB) closed at $285.94 in the latest trading session, marking a -1.43% move from the prior day.

  • GlobeNewswire

    Lecanemab Receives Priority Review Status in Japan

    TOKYO and CAMBRIDGE, Mass., Jan. 29, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that an application for manufacturing and marketing approval for lecanemab (generic name, U.S. brand name: LEQEMBI™), an anti-amyloid-β (Aβ) protofibril* antibody, in Japan has been designated for Priority Review by the Japanese Minis